Condor blog
Insights and practical guidance for modern clinical finance teams.

Leading biopharma R&D teams rely on Condor






The best product decisions we make don’t start in a roadmap meeting. They start on customer calls, when a clinical operations or FP&A leader tells us what’s still eating their week.
Over the past year, one topic kept coming up in almost every conversation: investigator grants intelligence.
The problem you described
Investigator grants account for up to 50% percent of total per-trial cost. A single mid-sized trial can generate tens of thousands of payment lines. Teams had two options, and neither worked:
- Take the vendor’s word for it. Most teams outsource grant payments to CROs or payments vendors who typically share summary reports — sometimes only a single dollar figure — with no visibility into which visits, procedures, or site fees it represents. Without line-level verification, sponsors pay for visits that never happened, procedures billed at off-contract rates, and duplicate charges, and they struggle to effectively forecast and understand how sites perform.
- Reconcile by hand. Sponsors that receive details from CROs and payment vendors must match thousands of payment lines, in formats that rarely line up with your own records, against site contracts and visit data. It’s slow, and at that volume, discrepancies still slip through.
Every investigator grant has three versions of the truth: what the contract says should happen, what your trial data says happened, and what the vendor says happened. Our customers already had the first two in Condor. The vendor’s version was the missing piece.
Today, I’m excited to share that’s no longer the case thanks to AI-powered investigator grants intelligence.
AI-powered investigator grants intelligence
Now you can upload vendor payment reports, procedure data, and visit data directly into Condor. Built on the Biopharma R&D Graph, our clinical and financial knowledge graph, Condor’s AI normalizes each vendor’s format and maps every line to your EDC activity, protocols, and site contracts.
Once reconciled, Condor surfaces:
- Overbilling and pricing discrepancies. Wrong prices, off-contract charges, and duplicates, checked against contracted rates, amendments, and terms.
- Missing and unmatched payments. Payments with no activity behind them, sites paid with no subject enrolled, and completed work that hasn’t been invoiced yet.
- Patterns over time. Sites and vendors that consistently overbill, lagging invoices, and the split between startup and patient spend.
Every finding links back to the underlying data, viewable by site, visit, procedure, and site admin fee. And because payment history is now connected to trial performance, those patterns feed Condor’s forecasting. Your projected spend reflects how vendors actually bill, not just what they invoiced.
The result: your team stops taking the vendor’s number on faith and starts walking into vendor conversations with evidence.
Our promise: AI that takes on the work that slows you down
This launch is part of a commitment we’ve made to our customers. We’re building AI that automates the workflows that bog biopharma R&D teams down, so R&D teams can make clinical and financial decisions more quickly and confidently.
In September, we launched our Clinical Finance AI Agent, which explains the “why” behind a forecast variance and builds the resulting scenario in seconds.
Five weeks later, we’re shipping investigator grants intelligence. Each launch follows the same pattern: find a workflow your team does by hand, understand it deeply, and build AI that runs it reliably, with every number traceable to its source.
What’s coming next
For investigator grants, the next step is moving from analysis on demand to continuous monitoring. Condor’s AI will watch payment and performance data as it arrives and flag anomalies the moment they appear. The site-level evidence it builds will also give you a stronger position when you negotiate CRO change orders.
Beyond grants, we have more AI agents coming in our product roadmap. I’m looking forward to sharing them soon.
If you’re a customer, connect with your customer success manager today to see AI-powered investigator grants intelligence in action on your own data. Not a Condor customer yet? Book a demo.
Recent posts

Optimizing Clinical Trial Finance: Best Practices for Collaborating with your CRO
In the rapidly evolving landscape of biotechnology, collaboration with Contract Research Organizations (CROs) is essential for successful clinical trials. However, it does not come without risk: upfront investment, hidden costs, and misaligned financial priorities to name a few. Effective financial management is crucial to ensure timely and accurate project execution, as well as audit preparedness. Here are best practices to enhance your partnership with CROs and optimize your clinical trial finances.
1. Establish Clear Contracts and Set Expectations
Define specific financial deliverables, timelines, and performance metrics in your vendor contract to avoid misunderstandings. Discuss expectations for reporting early to ensure continuous and timely flow of information throughout the study.
2. Regular Financial Reconciliation
Ensure frequent reconciliation between the CRO’s reported costs and your internal financial records. This helps prevent discrepancies and ensures that financial reports remain accurate and audit-ready.
→ Essential Reporting for Financial Health
To maintain optimal financial oversight when working with your CRO, ensure you have access to the following critical reports:
CRO Unit/Work Completed Tracker
- Require detailed, line-item level tracking from your CRO for direct fees (regardless of fixed-price or milestone-based contracts), along with transaction-level tracking for pass-through and investigator fees.
- Milestone payments do not accurately reflect the work completed, but rather are a tool for cashflow management. A comprehensive tracker for direct fees, pass-through costs, and investigator fees ensures transparency and alignment with the CRO’s estimate of expenses incurred, and will be required by auditors.
- Reporting should be monthly or quarterly, in alignment with your financial reporting cycle, and include a detailed task-by-task breakdown of units performed by the CRO.
Subject Visit Report
- Track patient metrics: screenings, enrollments, active participation, and completions.
- Use this data to accurately estimate investigator grants and verify CRO invoicing, especially for site and patient-related payments.
Additional Support Reports
- Screen Failure Report: Insight into patient drop-off rates.
- Unscheduled Visits Report: Track unexpected patient interactions.
- Invoiceables/Procedures Report: Ensure all billable activities are accounted for.
Site Listing
- Monitor recruitment, activation, and closure of study sites.
- Independently verify CRO reports to validate milestone payments.
IMV Report
- Assess your CRO’s monitoring activities and their completion status.
- Cross-reference this data to ensure accurate invoicing.
3. Collaborate on Budget Forecasting
Work closely with the CRO and other internal teams to develop accurate, realistic budgets, and update forecasts regularly. Integrating real-time data from both the CRO and internal teams can help monitor and adjust for any unexpected costs.
4. Use Integrated Financial Tools
Leverage financial software platforms that support real-time data exchange, automated accruals, and compliance tracking. This reduces manual errors and keeps finance teams aligned with clinical progress.
5. Establish a Communication and Reporting Cadence
Establish regular check-ins and reporting schedules with the CRO to stay updated on trial progress and financial impacts. Regular updates can prevent last-minute budget surprises and align the CRO’s work with financial goals.
→ Why an Invoice Isn’t Enough
CRO invoices are notoriously opaque. It is not uncommon to receive a multi-million dollar invoice with a single line item: Project Management.
To safeguard your finances:
- Request Line-Level Detail: During the study start-up and work order negotiation, ask for detailed reporting before invoicing. This helps confirm expenses against your independent, activity-based estimates.
- Leverage Real Study Data: If there are discrepancies, use your detailed expense estimates to discuss variances with your CRO.
6. Define Risk Management Protocols
Plan for potential cost overruns and delays by building contingency funds and risk management strategies into the budget. This ensures financial flexibility when dealing with unexpected clinical outcomes.
Avoid the black box, and be proactive in managing change orders to prevent unexpected costs and surprise retrospective invoices:
- Identify Hidden Costs: Watch for price increases, volume changes, mistakes, and duplicate items.
- Perform Line-Level Comparisons: Analyze your current work order against any upcoming changes. Use tools like specialized software to simplify your review.
- Validate New Additions: Ensure any new line items are indeed necessary and avoid unnecessary duplication.
Conclusion: Trust but verify
Navigating the complexities of clinical trials requires a strategic approach to financial management, especially when partnering with CROs. Establishing clear contracts, maintaining robust financial oversight, and fostering open communication, allows clinical finance organizations to enhance collaboration with CROs and mitigate financial risks. By prioritizing transparency and proactive planning, you can ensure that your partnership with CROs not only meets your financial goals but also supports the broader mission of advancing innovative therapies.
Read the article

Stop Straight-Lining, Start Scaling: The Key to Faster, More Accurate Accruals
Clinical trials are among the most complex financial endeavors in biotech, requiring careful financial planning, tracking, and reconciliation. Ensuring accurate financial reporting and vendor accountability means answering three key questions: What do we expect to happen? What has actually happened? And what is driving the variance between expectations and reality?
The Challenge of Forecasting Clinical Trial Costs
Unlike other industries where cost forecasting follows predictable patterns, clinical trials introduce many unpredictable variables. Enrollment rates, protocol amendments, and site-specific costs can make standard financial tools ineffective. Forecasting must be dynamic, aligning cost distributions with actual clinical drivers rather than relying on broad assumptions.
Accrual accounting—determining costs incurred but not yet paid—is another essential component. Many companies still rely on spreadsheets to manage this process, but doing so often leads to inefficiencies. When data is delayed or inaccurate, finance teams must choose between speed and accuracy, a trade-off that can complicate compliance and financial reporting.
The Pitfalls of Straight-Lining Costs
One common but problematic approach is straight-lining costs—spreading expenses evenly over time. While this method may seem simple and efficient, it often leads to major financial and compliance issues. Inaccurate accrual estimates can trigger audit misstatements, requiring time-consuming adjustments and increasing the risk of financial restatements.
A better alternative is to use activity-based accruals and multi-source triangulation—leveraging multiple data sources to validate costs. This approach provides a more accurate picture of clinical trial expenses and enhances financial reporting. While implementing an automated accrual system requires upfront effort, the long-term benefits include faster close times, improved audit readiness, and reduced financial risk.
Case Study: Ventyx’s Transition to Automated Accruals
Ventyx, a leading biopharmaceutical company, faced significant inefficiencies in their R&D accrual process. Heavy reliance on CRO reporting and manual processes led to long close cycles, frequent audit adjustments, and budgeting challenges. Managing multiple Phase 1 and Phase 2 trials further complicated financial forecasting.
By adopting an automated accrual platform, Ventyx reduced their monthly close process by 78%, completing it in under a week. The impact was significant:
- Efficiency: Faster and more reliable accrual processing.
- Accuracy: Fewer post-close adjustments and better compliance.
- Collaboration: Improved communication across finance, FP&A, and clinical operations.
- Vendor Management: Enhanced visibility and stronger contract negotiation capabilities.
- Audit Readiness: Strengthened SOX compliance and reduced audit-related inquiries.
As Roy Gonzales, Senior Vice President of Finance at Ventyx, stated:
"Previously, our close process spanned between 3 to 4 weeks and heavily relied on our CRO. Our new system enabled us to streamline our monthly close process, cutting it down to under a week."
Ventyx’s experience underscores a crucial point: organizations don’t have to choose between speed and accuracy. By leveraging automation, they can achieve both.
The Role of Automation in Clinical Trial Financial Management
As clinical trial portfolios grow, managing financial reporting manually becomes unsustainable. Automation bridges the gap between finance, accounting, and clinical operations by:
- Integrating vendor contracts, change orders, and out-of-scope costs in real time.
- Ensuring forecasts and actuals remain aligned.
- Providing structured data that enhances transparency and decision-making.
Organizations that invest in automation transition from reactive financial management to proactive strategic oversight. By removing inefficiencies and enhancing data accuracy, finance teams can support broader business objectives more effectively.
Final Thoughts
Clinical trial financial management requires a delicate balance between efficiency and accuracy. While straight-lining costs may seem like an easy solution, it often creates more problems in the long run. Investing in automation, adopting multi-source triangulation, and aligning finance with clinical operations can ensure long-term financial stability.
The takeaway is clear: accurate, fast, and compliant accruals are not mutually exclusive. By making the right investments, biotech companies can streamline operations and gain greater financial control.
Read the article

Clinical Trial Reconciliation Best Practices
Clinical trials often involve complex, high-value contracts that require reconciliation as the trial nears its conclusion. With varied payment structures and contract terms, it’s crucial to understand your obligations to ensure that the final reconciliation is transparent, accurate, and fair for both parties.
Know Your Contract
Understand the Payment Structure
- Unit-based: Vendor bills monthly for work completed.
- Time and Materials: Vendor bills monthly for hours worked and associated costs.
- Milestone-based: Vendor bills a percentage of the contract value upon reaching key milestones (e.g., Last Site Activated, Last Patient In, Database Lock).
Considerations for Early Trial Termination
Minimize Carrying Costs: Immediately stop unnecessary activities (like meetings) after trial cancellation to avoid additional billing.
Blended Line Items: Review blended line items that include multiple activities to ensure they match actual trial activities.
- Monthly management units that require varying levels of effort throughout the trial are impacted most by this
- Project Management
- Clinical Team Management
- Meeting/Teleconference line items
- Usually include varying attendees required throughout the trial timeline
- Other common line items impacted
- Regulatory submissions
- ICF related units
- Database Migrations
- Protocol Amendments
- Minor vs. Major
Milestone Contracts: If milestones were not met, ensure vendors report actual work completed, not just based on invoices.
Additional Considerations
- Upfront Retainers: Track retainer balances in invoices and understand when they are drawn down and replenished. See the “Managing Upfront Payments” resource for details.
- Bonus/Penalty Clauses: Be clear about any contract clauses that could affect final costs or result in credits.
- Inflation Clauses: Clarify how inflation adjustments are calculated, especially if the trial timeline shifts.
Reconciliation Overview
The reconciliation process is the same across payment structures:
Total Cost Incurred −Total Amount Paid = Final Reconciliation Value
- Total Cost Incurred: The final contract value determined by the vendor and agreed upon by the sponsor.
- Total Amount Paid: All payments made to the vendor to date.
Documents to Request for Reconciliation
To confirm Total Costs Incurred, request:
- Final Budget with a detailed line item breakdown.
- Unit Tracker showing completed tasks by month.
- Record of all pass-through transactions and site payments made by the vendor.
- Site Listings: Includes recruitment, activation, and deactivation dates to validate site-related budget items.
- Final EDC Reports:
- Subject Visits Summary: Confirms patient visits by site.
- Invoiceable Reports: Verifies invoiceable activities.
- Final Visit Report: Tracks patient activity and final visits, useful in early trial shutdowns.
- Monitoring Visit Listings: Compares completed visits to the budget.
- Independent Expense Estimates: Use real trial data to assess the reasonableness of the final contract value.
To confirm Total Invoices Paid, request:
- Vendor-provided invoicing summary of all invoices sent and received payments.
- Internal invoicing summary of all payments made to the vendor.
Software Tools
- Clinical Trial Finance and Accounting Software: Newly adopted technologies that utilize real clinical trial data in tandem with all of the vendor contracts to produce a defensible estimate of trial spend in relation to the contracted terms. This provides a reasonability check against the final contract value the vendor is requiring.
- Investigator Grants Payment Software: Provide more clarity into what is being invoiced from each site and enable a more streamlined payment process.
- Automated Invoicing Software: Some ERPs are equipped to support automated invoicing with your vendor to provide transparency and alignment of all transactions, enabling a clear understanding across parties of the invoicing position per contract.
Benefits to Software Tools
- Automated workflows enable swift decision making and ease of scaling
- Utilize defensible clinical trial data to support calculations
Final Reconciliation Documentation
Once the final contract value and payments are agreed upon, memorialize the agreement in a final change order or closeout letter.
- A Final Change Order strikes the old contract and replaces it with the final budget.
- A Closeout Letter documents the final contract value rendered by the vendor.
Read the article




